Trends in the use of antiepileptic drugs among pregnant women in the US, 2001-2007: A medication exposure in pregnancy risk evaluation program study

Paediatric and Perinatal Epidemiology

Volumn 26, Issue 6, 2012, Pages 578-588

  Bobo, William V ^a   Davis, Robert L ^b   Toh, Sengwee ^c   Li, De Kun ^d   Andrade, Susan E ^e   Cheetham, T Craig ^b   Pawloski, Pamala ^f   Dublin, Sascha ^g   Pinheiro, Simone ^h   Hammad, Tarek ^h   Scott, Pamela E ^h   Epstein, Richard A ^a   Arbogast, Patrick G ⁱ   Morrow, James A ^a   Dudley, Judith A ^a   Lawrence, Jean M ^b   Avalos, Lyndsay A ^d   Cooper, William O ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b KAISER PERMANENTE   (United States)

^c HARVARD PILGRIM HEALTH CARE INSTITUTE   (United States)

^d DIVISION OF RESEARCH   (United States)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^f HEALTHPARTNERS RESEARCH FOUNDATION   (United States)

^g GROUP HEALTH RESEARCH INSTITUTE   (United States)

^h CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

ⁱ VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

anticonvulsant; antiepileptic drugs; drug utilisation; pregnancy; prescription practices

Indexed keywords

ACETAZOLAMIDE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLONAZEPAM; CLORAZEPATE; DIAZEPAM; ETHOSUXIMIDE; ETHOTOIN; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; MEPHENYTOIN; MESUXIMIDE; METHARBITAL; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID; ZONISAMIDE;

ADULT; ARTICLE; DRUG SAFETY; EPILEPSY; EVALUATION; FEMALE; HUMAN; MENTAL DISEASE; NEUROMUSCULAR DISEASE; PAIN; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; PREVALENCE; RISK ASSESSMENT; SLEEP DISORDER; UNITED STATES;

EID: 84867520137     PISSN: 02695022     EISSN: 13653016     Source Type: Journal    
DOI: 10.1111/ppe.12004     Document Type: Article

References (41)

1. Spina E, Perugi G,. Antiepileptic drugs: indications other than epilepsy. Epileptic Disorders 2004; 6: 57-75. (Pubitemid 38808120)
2. EURAP Study Group. Utilization of antiepileptic drugs during pregnancy: comparative patterns in 38 countries based on data from the EURAP registry. Epilepsia 2009; 50: 2305-2309.
3. Vajda FJ, Hollingworth S, Graham J, Hitchcock AA, O'Brien TJ, Lander CM, et al,. Changing patterns of antiepileptic drug use in pregnant Australian women. Acta Neurologica Scandinavica 2010; 121: 89-93.
4. Cunnington MC, Weil JG, Messenheimer JA, Ferber S, Yerby M, Tennis P,. Final results from 18 years of the International Lamotrigine Pregnancy Registry. Neurology 2011; 76: 1817-1823.
5. Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sabers A, et al,. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology 2011; 10: 609-617.
6. Molgaard-Nielsen D, Hviid A,. Newer-generation antiepileptic drugs and the risk of major birth defects. Journal of the American Medical Association 2011; 305: 1996-2002.
7. Vajda FJ, Graham JE, Hitchcock AA, O'Brien TJ, Lander CM, Eadie MJ,. Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. Seizure 2010; 19: 558-561.
8. Vajda FJ, Graham J, Roten A, Lander CM, O'Brien TJ, Eadie M,. Teratogenicity of the newer antiepileptic drugs-the Australian experience. Journal of Clinical Neuroscience 2012; 19: 57-59.
9. Ackers R, Besag FM, Wade A, Murray ML, Wong IC,. Changing trends in antiepileptic drug prescribing in girls of child-bearing potential. Archives of Disease in Childhood 2009; 94: 443-447.
10. Palmieri C, Canger R,. Teratogenic potential of the newer antiepileptic drugs: what is known and how should this influence prescribing? CNS Drugs 2002; 16: 755-764. (Pubitemid 35252724)
11. Morrow J, Russell A, Guthrie E, Parsons L, Robertson I, Waddell R, et al,. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. Journal of Neurology, Neurosurgery, and Psychiatry 2006; 77: 193-198. (Pubitemid 43220841)
12. Andrade SE, Lo JC, Roblin D, Fouayzi H, Connor DF, Penfold RB, et al,. Antipsychotic medication use among children and risk of diabetes mellitus. Pediatrics 2011, 128: 1135-1141.
13. Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Mathews TJ, Kirmeyer S, et al,. Births: final data for 2007. National Vital Statistics Reports 2010; 58: 1-85.
14. Piper JM, Mitchel EF, Jr, Snowden M, Hall C, Adams M, Taylor P,. Validation of 1989 Tennessee birth certificates using maternal and newborn hospital records. American Journal of Epidemiology 1993; 137: 758-768. (Pubitemid 23145431)
15. Raebel MA, Ellis JL, Andrade SE,. Evaluation of gestational age and admission date assumptions used to determine prenatal drug exposure from administrative data. Pharmacoepidemiology and Drug Safety 2005; 14: 829-836. (Pubitemid 43056108)
16. Toh S, Mitchell AA, Werler MM, Hernandez-Diaz S,. Sensitivity and specificity of computerized algorithms to classify gestational periods in the absence of information on date of conception. American Journal of Epidemiology 2008; 167: 633-640. (Pubitemid 351430939)
17. Perucca E,. An introduction to antiepileptic drugs. Epilepsia 2005; 46 (Suppl. 4): 31-37. (Pubitemid 40847381)
18. National Collaborating Centre for Primary Care. The Epilepsies: The Diagnosis and Management of the Epilepsies in Adults and Children in Primary and Secondary Care. London: National Institute for Health and Clinical Excellence, 2004.
19. Trimble MR,. On the use of tranquillisers in epilepsy. Epilepsia 2002; 43 (Suppl. 2): 25-27. (Pubitemid 34229482)
20. Riss J, Cloyd J, Gates J, Collins S,. Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurologica Scandinavica 2008; 118: 69-86.
21. Marchetti F, Romero M, Bonati M, Tognoni G,. Use of psychotropic drugs during pregnancy. A report of the international co-operative drug use in pregnancy (DUP) study. Collaborative Group on Drug Use in Pregnancy (CGDUP). European Journal of Clinical Pharmacology 1993; 45: 495-501. (Pubitemid 24036925)
22. McElhatton PR,. The effects of benzodiazepine use during pregnancy and lactation. Reproductive Toxicology 1994; 8: 461-475.
23. Bergman U, Rosa FW, Baum C, Wiholm BE, Faich GA,. Effects of exposure to benzodiazepine during fetal life. Lancet 1992; 340: 694-696.
24. Meador K, Reynolds MW, Crean S, Fahrbach K, Probst C,. Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Research 2008; 81: 1-13.
25. Cummings C, Stewart M, Stevenson M, Morrow J, Nelson J,. Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood 2011; 96: 643-647.
26. Vinten J, Bromley RL, Taylor J, Adab N, Kini U, Baker GA,. The behavioral consequences of exposure to antiepileptic drugs in utero. Epilepsy & Behavior 2009; 14: 197-201.
27. Perucca E,. Birth defects after prenatal exposure to antiepileptic drugs. Lancet Neurology 2005; 4: 781-786. (Pubitemid 41457294)
28. Johannessen LC, Larsson PG, Rytter E, Johannessen SI,. Antiepileptic drugs in epilepsy and other disorders-a population-based study of prescriptions. Epilepsy Research 2009; 87: 31-39.
29. Alacqua M, Trifiro G, Spina E, Moretti S, Tari DU, Bramanti P, et al,. Newer and older antiepileptic drug use in Southern Italy: a population-based study during the years 2003-2005. Epilepsy Research 2009; 85: 107-113.
30. Hollingworth SA, Eadie MJ,. Antiepileptic drugs in Australia: 2002-2007. Pharmacoepidemiology and Drug Safety 2010; 19: 82-89.
31. Hsieh LP, Huang CY,. Trends in the use of antiepileptic drugs in Taiwan from 2003 to 2007: a population-based national health insurance study. Epilepsy Research 2011; 96: 81-88.
32. Tsiropoulos I, Gichangi A, Andersen M, Bjerrum L, Gaist D, Hallas J,. Trends in utilization of antiepileptic drugs in Denmark. Acta Neurologica Scandinavica 2006; 113: 405-411. (Pubitemid 44046326)
33. Shih JJ, Ochoa JG,. A systematic review of antiepileptic drug initiation and withdrawal. The Neurologist 2009; 15: 122-131.
34. Viguera AC, Nonacs R, Cohen LS, Tondo L, Murray A, Baldessarini RJ,. Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. American Journal of Psychiatry 2000; 157: 179-184. (Pubitemid 30080895)
35. Viguera AC, Whitfield T, Baldessarini RJ, Newport DJ, Stowe Z, Reminick A, et al,. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. American Journal of Psychiatry 2007; 164: 1817-1824. (Pubitemid 351739234)
36. Deckers CL,. Overtreatment in adults with epilepsy. Epilepsy Research 2002; 52: 43-52. (Pubitemid 35351531)
37. Conca A, Grohmann R, Di PJ, Hausmann A,. Is there a rationale in combining anticonvulsants for bipolar patients? Neuropsychiatrie 2007; 21: 159-171. (Pubitemid 47047182)
38. Holmes LB, Mittendorf R, Shen A, Smith CR, Hernandez-Diaz S,. Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Archives of Neurology 2011; 68: 1275-1281.
39. Davis RL,. Medication exposure in pregnancy risk evaluation program (MEPREP). Journal of Population Therapeutics and Clinical Pharmacology 2010; 17: e336-e340.
40. Ray WA, Griffin MR,. Use of Medicaid data for pharmacoepidemiology. American Journal of Epidemiology 1989; 129: 837-849. (Pubitemid 19094261)
41. Ray WA,. Population-based studies of adverse drug effects. New England Journal of Medicine 2003; 349: 1592-1594. (Pubitemid 37288566)